NYSEHealth CareMedical - DistributionSnapshot 2026-08-31
Reading COR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Operating margin near 12.5% next quarter: 1.3% vs 12.5% target.
Cencora is growing steadily with revenue up about 4% to 5% yearly. Profit margins are expected near 12.5% next quarter. The company raised its EPS guidance to about $17.8 for fiscal 2026. It completed a $4.6 billion acquisition to expand healthcare solutions.
Growth could slow below analyst expectations of 7%. Profit margins might compress from the current raised guidance near 12.5%. Management changes and volatile execution could hurt results. Debt from acquisitions may pressure cash flow.
The stock price is about 4% above our fair value near $292, which is 18% below the Street median target. Analysts expect roughly 7% revenue growth, which aligns with company guidance. Our view is more conservative than the Street.
Breaks if: Share repurchases fall significantly short of $1 billion by end 2026
Breaks if: EPS guidance falls below $17.65 for fiscal 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on long-term growth. The current thesis state is intact, supported by strong recent financial performance and management execution.
The market seems to price COR as cheap compared to its peers, with a slight expectations gap. This suggests that investors are aware of the company's fragile earnings quality and volatile management but still see potential.
Fundamentals are likely to remain strong in the near term, as management is on track with key priorities like raising earnings guidance and integrating the OneOncology acquisition. However, there is a moderate risk due to past performance misses.
The thesis hinges on several factors, including the performance of key sector peers and any changes in guidance from management. A weakening jobs report could also negatively impact sentiment around COR and similar companies.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on COR. However, a potential increase in EPS guidance for fiscal 2026 poses a threat. Additionally, insider purchases by management may improve sentiment regarding their confidence in the company's future.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Cencora has raised its adjusted diluted EPS guidance range for fiscal 2026.
Breaks if: Operating margin falls below 11.5% next quarter
Cencora has raised its adjusted diluted EPS guidance range for fiscal 2026.
Breaks if: YoY revenue growth falls below 7% next year
Cencora has raised its adjusted diluted EPS guidance range for fiscal 2026.
Over the next 1 to 3 years, COR's performance will depend on its ability to sustain recent gains and navigate sector challenges. Not investment advice.
